Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine

J Pediatric Infect Dis Soc. 2021 Nov 11;10(10):962-966. doi: 10.1093/jpids/piab060.

Abstract

On May 10, 2021, the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) was expanded to include adolescents (May 10, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use). We describe clinical characteristics of 8 adolescents who presented over the course of 36 days to Nicklaus Children's Hospital with perimyocarditis within 4 days of receiving a dose of BNT162b2 vaccine.

Keywords: BNT162b2; COVID-19 vaccine; myocarditis; pericarditis.

MeSH terms

  • Adolescent
  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Child
  • Humans
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • BNT162 Vaccine